Banque Pictet & Cie SA Has $4.77 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Banque Pictet & Cie SA increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 838.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 51,621 shares of the biopharmaceutical company’s stock after buying an additional 46,121 shares during the quarter. Banque Pictet & Cie SA’s holdings in Gilead Sciences were worth $4,768,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC raised its stake in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the period. nVerses Capital LLC acquired a new position in Gilead Sciences during the 3rd quarter worth approximately $25,000. YANKCOM Partnership acquired a new position in Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the 4th quarter worth approximately $29,000. Finally, Valued Wealth Advisors LLC increased its holdings in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total value of $14,073,240.72. Following the transaction, the chief financial officer now owns 171,223 shares of the company’s stock, valued at $17,502,415.06. This represents a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 710,500 shares of company stock valued at $67,684,956 over the last 90 days. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on GILD. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday. Robert W. Baird boosted their price objective on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Morgan Stanley boosted their price objective on Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday. Piper Sandler boosted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Mizuho upped their target price on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Eleven equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $101.33.

Gilead Sciences Trading Down 1.8 %

NASDAQ:GILD opened at $104.08 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $106.69. The company has a market cap of $129.71 billion, a P/E ratio of 1,156.44, a P/E/G ratio of 1.25 and a beta of 0.18. The stock’s fifty day moving average price is $93.63 and its two-hundred day moving average price is $87.37.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. As a group, analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.